Citizens Initiates Coverage On Avalo Therapeutics with Market Outperform Rating, Announces Price Target of $52

Benzinga Newsdesk www.benzinga.com Positive 79.0%

Neg 0% Neu 0% Pos 79%

Citizens analyst Jason Butler initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Market Outperform rating and announces Price Target of $52.